Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

Core Insights - Nuvation Bio Inc. has initiated the enrollment of the first patient in the TRUST-IV Phase 3 study, which aims to evaluate the efficacy and safety of IBTROZI™ (taletrectinib) compared to placebo for the adjuvant treatment of resected ROS1-positive early-stage non-small cell lung cancer (NSCLC) [1] Company Summary - Nuvation Bio Inc. is a global oncology company focused on addressing significant challenges in cancer treatment [1] - The company is conducting a Phase 3 study to assess a next-generation ROS1 inhibitor, IBTROZI™, in patients with ROS1-positive NSCLC [1]